"AOD9604 - Important Clarifications" (PDF)
What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
In response, cervical stretching stimulates additional oxytocin to be synthesized by the hypothalamus and released from the pituitary
The expiration date of the Methylcobalamin is on each individual ampoule
The primary antibodies were anti-TNC (1:100, bs-1039R), anti-ColI (bs-10423R), anti-SCXA (bs-12364R), and anti-TNMD (bs-7525R) from Bioss
The marketing is confident